Načítá se...
Development of siRNA payloads to target KRAS-mutant cancer
RNA interference (RNAi) is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We employed a functional “Senso...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184972/ https://ncbi.nlm.nih.gov/pubmed/25100204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0900 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|